

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2024-25/0014

July 26, 2024

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Listing Department
National Stock Exchange of India
Limited
"Exchange Plaza", 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051

Scrip Code: 532637

Symbol: MANGALAM

Sub: Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 - Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2024

Dear Sir/Madam,

Pursuant to Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed the Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2024.

We request your good office to kindly take the above certificate on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,
For Mangalam Drugs & Organics Limited

Govardhan M. Dhoot
Managing Director
DIN:01240086



Mustafa Bohra & Associates Practising Company Secretaries

Address: Office No. B- 08 & 10, Wadala Udyog Bhawan, MMGS Marg,
Dadar (E), Wadala, Mumbai – 400031, Maharashtra, India.

Contact: +91 79996-65955 / +91 76930-19852 | **Email ID:** mustafa@asdt.in

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT FOR QUARTER ENDED JUNE, 2024

UNDER REGULATION 76 OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018

To,

MANGALAM Drugs & Organics Limited (Hereinafter referred to as Company)

CIN: L24230MH1972PLC116413

Address: 3rd Floor, RUPAM Building, 239, P.D'
Mello Road, Near G.P.O., Mumbai – 400001,
Maharashtra, India.

Dear Sirs / Madam,

We have examined the relevant books, registers, forms, documents and papers produced before us by MANGALAM Drugs & Organics Limited and LINK INTIME India Private Limited, Registrars and Transfer Agent of the Company in respect of Reconciliation of Share Capital Audit as per the Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

To the best of our knowledge and according to the information and explanations given to us and as shown by the electronic records examined by us, we certify the following:

1.	For Quarter Ended	:	June, 2024
2.	ISIN	:	INE584F01014
3.	Face Value	:	Rs. 10/- each
4.	Name of the Company	:	Mangalam Drugs and Organics Limited
5.	Registered Office Address	:	3 rd Floor, Rupam Building 239, P. D' Mello Road Mumbai -400001, Maharashtra, India

6.	Correspondence Address	:	3 rd Floor, Rupam Building 239, P. D' Mello Road Mumbai -400001, Maharashtra, India	
7.	Telephone & Fax No.	:	Tel. 022-22616200 / 6300 / 8787 Fax 022- 22619090	
8.	Email Address	:	contactus@mangalamdrugs.com	
9.	Website	:	https://www.mangalamdrugs.com/	
10.	Name of the stock exchange where Company's Securities are Listed	:	BSE and NSE	
			No. of shares	% Of Total Issued capital
11.	Issued Capital	:	1,58,28,248	100 %
12.	Listed Capital	:	1,58,28,248	100 %
13.	Held in dematerialized form in CDSL	:	60,23,465	38.05 %
14.	Held in dematerialized form in NSDL	:	98,04,773	61.95 %
15.	Physical	:	10	0.00 %
16.	Total No. of Shares (13+14+15)	:	1,58,28,248	100 %
17.	Reason for difference if any, between (11 & 12), (11 & 16), (12 & 16)	:	NA	NA
18.	Certifying the details of Changes in Share Capital during quarter under consideration as per Table below: Nil			

Particulars*	No of Shares	Applied / Not applied For listing	Listed on Stock Exchange (specify Name) for listing	Whether intimated to CDSL	Whether intimated to NSDL	In- Principal approval pending for Stock Exchange (specify names)
No Change						

* Rights, Bonus, Preferential Issue, ESOP's, Amalgamation, Conversion, buy back, Capital Reduction, Forfeiture, any other (to specify).

19.	Register of Members is updated (Yes / No)	:	Yes
20.	Reference to previous quarter with regards to excess	:	Not Applicable

	dematerialization of shares, if any																
21.	Has the company resolved the matter mentioned in Point No. 20 above in the Current Quarter	:	Not Applicable														
22.	Mention the total no. of Request, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay	:	<table border="1"> <thead> <tr> <th>Total No. of Demat Requests</th> <th>No. of Requests</th> <th>No. of Shares</th> <th>Reasons for Delay</th> </tr> </thead> <tbody> <tr> <td>Confirmed after 21 days</td> <td>Nil</td> <td>Nil</td> <td>Nil</td> </tr> <tr> <td>Pending for more than 21 Days</td> <td>Nil</td> <td>Nil</td> <td>Nil</td> </tr> </tbody> </table>	Total No. of Demat Requests	No. of Requests	No. of Shares	Reasons for Delay	Confirmed after 21 days	Nil	Nil	Nil	Pending for more than 21 Days	Nil	Nil	Nil		
Total No. of Demat Requests	No. of Requests	No. of Shares	Reasons for Delay														
Confirmed after 21 days	Nil	Nil	Nil														
Pending for more than 21 Days	Nil	Nil	Nil														
23.	Name, Telephone & Fax No. of the Compliance officer of the Company as on 30.06.2024	:	Mr. Jayant Barde Membership No: A61954 Tel No : 022-22616200 / 6300 / 8787 Fax No : 022-22619090														
24.	Name, Telephone & Fax No. of the Compliance officer of the Company as on date of signing this report	:	Ms. Anuradha Pandey Membership No: A72902 Tel No : 022-22616200 / 6300 / 8787 Fax No : 022-22619090														
25.	Name, Address, Telephone, Registration No. of the Auditor	:	M/s. Mustafa Bohra & Associates Mr. Mustafa Bohra Practising Company Secretaries Address: Office No. B- 08 & 10, Wadala Udyog Bhawan, MMGS Marg, Dadar (E), Wadala, Mumbai – 400031, Maharashtra, India Contact No : +91 79996-65955 Email ID : mustafa@asdt.in M. No. : A61727 COP No : 24345 FRN : S2021MP794700 Peer Review Certificate No: 5680														
26.	Appointment of common agency for share registry work if yes (Name & Address)	:	LINK INTIME India Private Limited, Address: C - 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai – 400083, Maharashtra, India. Tel No : +91 22 4918 6000 Email ID : mumbai@linkintime.co.in / rnt.helpdesk@linkintime.co.in														

27.	Any other details that the Auditor may like to provide (E.g., BIFR Company, delisting from SE, Company changed its Name, etc.)	The Board of Directors of the Company in its meeting held on 18 th June, 2024 has approved Scheme of Merger by Absorption of Mangalam Laboratories Private Limited (First Transferor Company) and Shri JB Pharma Private Limited (<i>Formerly known as Shri JB Pharma LLP</i>) (Second Transferor Company) with Mangalam Drugs and Organics Limited (Transferee Company). The Company is in process to obtain No Objection Certificate from BSE and NSE as per Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
-----	--	--

Place : Mumbai
Date : 23.07.2024

M/s. Mustafa Bohra & Associates
Practising Company Secretaries



Mr. Mustafa Bohra
Proprietor
ACS : 61727
C.P No : 24345
FRN : S2021MP794700
PR No : 5680
UDIN : A061727F000801543